| Literature DB >> 31514266 |
André Pereira1,2, Nazli Ayhan3, José Manuel Cristóvão4,5, Hugo Vilhena6,7,8, Ângela Martins9, Patrícia Cachola10, Joaquim Henriques11, Mónica Coimbra12, Ana Catarino13, Tereza Lestinova14, Tatiana Spitzova15, Petr Volf16, Lenea Campino17, Remi Charrel18, Carla Maia19,20.
Abstract
Phlebotomine sand fly-borne pathogens such as Leishmania spp. and phleboviruses are emerging threats to humans and animals worldwide. The aim of this work was to evaluate the exposure of cats from Portugal to Toscana virus (TOSV) and Sandfly Fever Sicilian virus (SFSV) and assess the associated risk factors. The possible association between exposure to Phlebotomus perniciosus saliva with TOSV and SFSV was also investigated. Out of 369 cats tested, 18 (4.9%, n = 365) were seropositive for TOSV, and eight (2.2%, n = 367) were seropositive for SFSV. Multivariate logistic regression analysis showed that cats presenting clinical signs that were compatible with leishmaniosis and antibodies to TOSV had a significantly higher risk of being SFSV seropositive. The presence of antibodies to sand fly-borne viruses in cats indicate that these animals are frequently exposed to sand flies and transmitted pathogens. Data suggest that cats can be used to qualitatively monitor human exposure to TOSV and SFSV in endemic areas. The clinical impact of SFSV in cats' health should be investigated. The identification of the sand fly species responsible for the circulation of TOSV and SFSV in nature and the evaluation of the vectorial competence of P. perniciosus to SFSV should also be addressed.Entities:
Keywords: Bunyavirales; Phenuiviridae; Phlebotomus perniciosus; Phlebovirus; Sandfly Fever Sicilian Virus; Toscana virus; arbovirus; cat; saliva
Year: 2019 PMID: 31514266 PMCID: PMC6780191 DOI: 10.3390/microorganisms7090339
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Seroprevalence of antibodies against Sandfly Fever Sicilian virus (SFSV) and Toscana virus (TOSV) in cats from Portugal.
| Variable/Categories | Antibodies to SFSV | Antibodies to TOSV | ||
|---|---|---|---|---|
| Tested, | Positive, | Tested, | Positive, | |
| Sex | 366 | 364 | ||
| Female | 204 (55.7) | 2 (1.0; 0.3–3.5) | 203 (55.8) | 10 (4.9; 2.7–8.8) |
| Male | 162 (44.3) | 6 (3.7; 1.7–7.8) | 161 (44.2) | 8 (5.0; 2.5–9.5) |
| Age group | 330 | 328 | ||
| 2–11 months | 76 (23.0) | 0 (0.0; 0.0–4.8) | 77 (23.5) | 1 (1.3; 0.2–7.0) |
| 12–35 months | 71 (21.5) | 1 (1.4; 0.2–7.6) | 71 (21.6) | 3 (4.2; 1.4–11.7) |
| 36–95 months | 91 (27.6) | 2 (2.2; 0.6–7.6) | 91 (27.7) | 4 (4.4; 1.7–10.7) |
| More than 95 months | 92 (27.9) | 5 (5.4; 2.3–12.1) | 89 (27.1) | 8 (9.0; 4.6–16.8) |
| Reproductive status | 352 | 350 | ||
| Entire | 239 (67.9) | 4 (1.7; 0.7–4.2) | 240 (68.6) | 9 (3.8; 2.0–7.0) |
| Neutered | 113 (32.1) | 3 (2.7; 0.9–7.5) | 110 (31.4) | 9 (8.2; 4.4–14.8) |
| Breed | 366 | 364 | ||
| Defined | 14 (4.6) | 0 (0.0; 0.0–21.5) | 16 (4.4) | 2 (12.5; 3.5–36.0) |
| Mongrel | 349 (95.4) | 8 (2.3; 1.2–4.5) | 348 (95.6) | 16 (4.6; 2.9–7.3) |
| Fur length | 366 | 364 | ||
| Short | 328 (89.6) | 8 (2.4; 1.2–4.7) | 327 (89.8) | 17 (5.2; 3.2–8.2) |
| Medium or long | 38 (10.4) | 0 (0.0; 0.0–9.2) | 37 (10.2) | 1 (2.7; 0.5–13.8) |
| Lifestyle | 362 | 360 | ||
| Domestic | 152 (42.0) | 4 (2.6; 1.0–6.6) | 148 (41.1) | 13 (8.8; 5.2–14.5) |
| Shelter/stray | 210 (58.0) | 3 (1.4; 0.5–4.1) | 212 (58.9) | 4 (1.9; 0.7–4.8) |
| Region | 367 | 365 | ||
| Center | 62 (16.9) | 2 (3.2; 0.9–11.0) | 60 (16.4) | 8 (13.3; 6.9–24.2) |
| Lisbon metropolitan area | 285 (77.7) | 6 (2.1; 1.0–4.5) | 285 (78.1) | 8 (2.8; 1.4–5.4) |
| Alentejo | 5 (1.4) | 0 (0.0; 0.0–43.5) | 5 (1.4) | 1 (20.0; 3.6–62.4) |
| Algarve | 15 (4.1) | 0 (0.0; 0.0–20.4) | 15 (4.1) | 1 (6.7; 1.2–29.8) |
| Other animals | 362 | 360 | ||
| No | 45 (12.4) | 0 (0.0; 0.0–7.9) | 43 (11.9) | 3 (7.0; 2.4–18.6) |
| Yes | 317 (87.6) | 7 (2.2; 1.1–4.5) | 317 (88.1) | 13 (4.1; 2.4–6.9) |
| Ectoparasiticides | 350 | 348 | ||
| No | 277 (79.1) | 4 (1.4; 0.6–3.7) | 275 (79.0) | 9 (3.3; 1.7–6.1) |
| Yes | 73 (20.9) | 4 (5.5; 2.2–13.3) | 73 (21.0) | 8 (11.0; 5.7–20.2) |
| Clinical signs | 367 | 365 | ||
| No | 258 (70.3) | 2 (0.8; 0.2–2.8) | 258 (70.7) | 12 (4.7; 2.7–8.0) |
| Yes | 109 (29.7) | 6 (5.5; 2.5–11.5) | 107 (29.3) | 6 (5.6; 2.6–11.7) |
| Concomitant diseases | 187 | 185 | ||
| No | 97 (51.9) | 2 (2.1; 0.6–7.2) | 97 (52.4) | 4 (4.1; 1.6–10.1) |
| Yes | 90 (48.1) | 4 (4.4; 1.7–10.9) | 88 (47.6) | 9 (10.2; 5.4–18.3) |
| Phlebotomine activity period | 367 | 365 | ||
| No | 201 (54.8) | 3 (1.5; 0.5–4.3) | 200 (54.8) | 7 (3.5; 1.7–7.0) |
| Yes | 166 (45.2) | 5 (3.0; 1.3–6.9) | 165 (45.2) | 11 (6.7; 3.8–11.5) |
| Antibodies to | 326 | 325 | ||
| Negative | 178 (54.6) | 1 (0.6; 0.1–3.1) | 178 (54.8) | 5 (2.8; 1.2–6.4) |
| Positive | 148 (45.4) | 7 (4.7; 2.3–9.4) | 147 (45.2) | 10 (6.8; 3.7–12.1) |
| Antibodies to | 367 | 365 | ||
| Negative | 344 (93.7) | 8 (2.3; 1.2–4.5) | 342 (93.7) | 17 (5.0; 3.1–7.8) |
| Positive | 23 (6.3) | 0 (0.0; 0.0–14.3) | 23 (6.3) | 1 (4.3; 0.8–21.0) |
| Antibodies to TOSV | 363 | NA | ||
| Negative | 345 (95.0) | 5 (1.4; 0.6–3.3) | ||
| Positive | 18 (5.0) | 3 (16.7; 5.8–39.2) | ||
| Antibodies to SFSV | NA | 363 | ||
| Negative | 355 (97.8) | 15 (4.2; 2.6–6.8) | ||
| Positive | 8 (2.2) | 3 (37.5; 13.7–69.4) | ||
| Total | 367 | 8 (2.2; 1.1–4.2) | 365 | 18 (4.9; 3.1–7.7) |
Abbreviations: CI, 95% confidence interval; NA, not applicable.